Koensgen D et al. – This study evaluated the expression, localization, and prognostic implications of plasminogen activator inhibitor type 1 (PAI-1) and PAI-1 ribonucleic acid (RNA)-binding protein 1 (RBP1) in primary and recurrent ovarian cancer (OC). The study concluded that combination of PAI-1 and PAI-RBP1 may represent as a new prognostic factor for OC; however, prospective trials are required to confirm this further.

Methods

• A total of 156 patients with OC were analyzed for the presence of PAI-1 and PAI-RBP1, followed by correlation with significant clinicopathological parameters.

Results

• PAI-1 and PAI-RBP1 were shown to be predictive markers for outcomes in patients with OC.
• A significant correlation was observed between PAI-1 levels and volume of ascites, Federation of Gynecology and Obstetrics staging, and lymph node status, whereas expression of PAI-RBP1 was correlated with age at first diagnosis, histological tumor type, presence of distant metastasis (pM), and recurrence.
• While PAI-1 revealed a trend toward association, PAI-RBP1 was significantly associated with progression-free survival.
• PAI-1 protein in recurrent OC tissues was shown to be primarily localized in the nucleus.